LONDON, England – An extension to the current UK approval of the Spikevax vaccine (formerly COVID-19 Vaccine Moderna) that allows its use in 12- to 17-year-olds has today been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
This Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in Great Britain only and was approved via the European Commission (EC) Decision Reliance Route. This is when the marketing authorisation application made by the company references the decision made by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
Spikevax is authorised in children aged 12-17 years in Northern Ireland under the CMA extension granted by the European Medicines Agency on July 23, 2021.
Dr June Raine, MHRA chief executive, said: “I am pleased to confirm that that the COVID-19 vaccine made by Moderna has now been authorised in 12-17-year-olds. The vaccine is safe and effective in this age group.
“We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 17-year age group. It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise on whether this age group should be vaccinated with the COVID-19 vaccine made by Moderna as part of the deployment programme.”
